Cadila-Hetero Slugfest Over The ‘Hep’ Tag
This article was originally published in PharmAsia News
Executive Summary
Trademark disputes continue unabated in Indian courts, this time involving generic versions of Bristol-Myers Squibb's hepatitis C therapy, Daklinza (daclatasvir) marketed by the local firms Cadila Healthcare and Hetero.